YY1 in the Control of the Pathogenesis and Drug Resistance of Cancer
A Critical Therapeutic Target

Presents important knowledge on YY1 as a potential new biomarker for early cancer diagnosis, response to conventional treatments, and new drugs

Benjamin Bonavida (Edited by)

9780128219096, Elsevier Science

Hardback, published 20 October 2020

360 pages
23.4 x 19 x 2.5 cm, 1.02 kg

YY1 Is Pivotal in the Control of the Pathogenesis and Drug Resistance of Cancer: A Critical Therapeutic Target describes the current state-of-the-art of the transcription factor YY1 that is overexpressed in the majority of cancers and a central factor that regulates all of the major features and characteristics of human cancers. This book emphasizes the biochemical, molecular and genetic underlying mechanisms by which YY1 regulates its pro-cancerous activities. In addition, it also describes the role of YY1 in the regulation of tumor cell resistance to conventional chemo and immunotherapies and the important role of inhibiting YY1 in cancer.

1. General introduction of YY12. Expression of YY1 in various human cancers: Prognostic significance3. Regulation of YY1 transcription and post-transcription4. YY1 and proliferation5. Role of microRNAs targeting YY16. YY1 repression of various genes in various cancers7. YY1 regulation of EMT and metastasis8. YY1 regulation of the cancer stem cell phenotype 9. YY1 regulation of autophagy10. YY1 regulation of resistance to chemotherapy11. YY1 regulation of resistance to immunotherapy12. YY1 phosphorylation13. YY1 epigenetic regulation14. YY1 regulation of the Warburg Effect15. YY1 inhibitors16. YY1 versus YY217. Future perspectives and conclusions

Subject Areas: Life sciences: general issues [PSA]